BACKGROUND: The aim of this study was to evaluate the dosimetry for [177Lu]Lu-PSMA-617 in advanced non-prostate cancer (non-PCa) patients with previous intense radiotracer uptake of the tumor lesions on PET/CT using [68Ga]Ga-PSMA-11. This evidence concerns the gene FOLH1 and prostate carcinoma.